BIND Therapeutics Inc (BIND)

0.51
NASDAQ : Health Care
Prev Close 0.52
Day Low/High 0.49 / 0.54
52 Wk Low/High 0.35 / 5.52
Avg Volume 747.90K
Exchange NASDAQ
Shares Outstanding 20.89M
Market Cap 10.86M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BIND Therapeutics Provides Update On Chapter 11 Proceedings And Announces Agreement With Hercules Technology III, L.P.

BIND Therapeutics Provides Update On Chapter 11 Proceedings And Announces Agreement With Hercules Technology III, L.P.

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured lender Hercules...

Data Published In Journal Of Controlled Release Demonstrate Flexibility Of ACCURINS® To Encapsulate A Broad Range Of Physically And Chemically Diverse Payloads With High Encapsulation Efficiency And Tunable Release Kinetics

Data Published In Journal Of Controlled Release Demonstrate Flexibility Of ACCURINS® To Encapsulate A Broad Range Of Physically And Chemically Diverse Payloads With High Encapsulation Efficiency And Tunable Release Kinetics

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the publication of detailed methods for its hydrophobic ion pairing...

BIND Therapeutics Reports First Quarter 2016 Financial Results And Provides Business Update

BIND Therapeutics Reports First Quarter 2016 Financial Results And Provides Business Update

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the first quarter ended March 31,...

BIND Therapeutics Announces Collaboration With Affilogic To Provide BIND With Access To Targeting Ligands That Are Key Modulators Of Anti-tumor Immunity

BIND Therapeutics Announces Collaboration With Affilogic To Provide BIND With Access To Targeting Ligands That Are Key Modulators Of Anti-tumor Immunity

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced a research collaboration with Affilogic, a privately held...

BIND Therapeutics To Report First Quarter 2016 Financial Results On May 9, 2016

BIND Therapeutics To Report First Quarter 2016 Financial Results On May 9, 2016

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced it will host a conference call and audio webcast on May 9, 2016, at...

BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding

BIND Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Protection Proceeding

BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that it has elected to file a voluntary petition under Chapter 11 of...

BIND Therapeutics Reports Phase 2 Data From INSITE 1 And INSITE 2 Trials With BIND-014 And Provides Strategic Update

BIND Therapeutics Reports Phase 2 Data From INSITE 1 And INSITE 2 Trials With BIND-014 And Provides Strategic Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced preliminary top-line results from the BIND-014 (PSMA-targeted...

BIND Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Announces Shift In Research And Discovery Strategy To Focus On Developing Innovative Medicines Based On ACCURINS® Platform

BIND Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Announces Shift In Research And Discovery Strategy To Focus On Developing Innovative Medicines Based On ACCURINS® Platform

BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the fourth quarter and full year 2015.

BIND Therapeutics To Report Fourth Quarter And Year-End 2015 Financial Results On March 15, 2016

BIND Therapeutics To Report Fourth Quarter And Year-End 2015 Financial Results On March 15, 2016

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS ®, today announced it will host a conference call and live audio webcast on...

BIND Therapeutics And Synergy Pharmaceuticals Announce Collaboration To Develop ACCURINS® With Proprietary Uroguanylin Analogs For Targeting Gastrointestinal Receptors On Tumors

BIND Therapeutics And Synergy Pharmaceuticals Announce Collaboration To Develop ACCURINS® With Proprietary Uroguanylin Analogs For Targeting Gastrointestinal Receptors On Tumors

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, and Synergy Pharmaceuticals Inc.

ACCURIN Nanoparticle (Photo: Business Wire)

ACCURIN Nanoparticle (Photo: Business Wire)

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing innovative therapeutics called ACCURINS ®, today announced the publication of data highlighting the ability of ACCURIN polymeric...

BIND Therapeutics Provides Enrollment Update For Phase 2 INSITE 1 And INSITE 2 Trials With BIND-014

BIND Therapeutics Provides Enrollment Update For Phase 2 INSITE 1 And INSITE 2 Trials With BIND-014

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced that the iNSITE 1 trial in non-small cell lung cancer...

BIND Therapeutics Presents Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) At The 2016 Genitourinary Cancers Symposium

BIND Therapeutics Presents Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) At The 2016 Genitourinary Cancers Symposium

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS ®, today announced the presentation of complete data from its phase 2...

BIND Therapeutics To Present At Biotech Showcase 2016

BIND Therapeutics To Present At Biotech Showcase 2016

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced that Andrew Hirsch, BIND's president and chief executive...

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., As Chief Scientific Officer

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., As Chief Scientific Officer

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced the appointment of Jonathan Yingling, Ph.

BIND Therapeutics To Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort To Second Stage Of INSITE 1 Trial

BIND Therapeutics To Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort To Second Stage Of INSITE 1 Trial

BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced that the squamous histology non-small cell lung cancer...

BIND Therapeutics Announces Initiation Of Clinical Studies With Accurin AZD2811 In Solid Tumors

BIND Therapeutics Announces Initiation Of Clinical Studies With Accurin AZD2811 In Solid Tumors

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that AstraZeneca (NYSE: AZN) has initiated patient...

BIND Therapeutics To Present At 2015 Stifel Healthcare Conference

BIND Therapeutics To Present At 2015 Stifel Healthcare Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced that Andrew Hirsch, BIND's president and chief executive...

BIND Presents Data Demonstrating Ability Of Accurins To Improve Efficacy And Tolerability Of Multiple Anti-Cancer Agents

BIND Presents Data Demonstrating Ability Of Accurins To Improve Efficacy And Tolerability Of Multiple Anti-Cancer Agents

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today reported data demonstrating the efficacy and tolerability of...

BIND Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today reported financial results and business highlights for the third...

BIND Therapeutics' Presentations At Upcoming AACR-NCI-EORTC Conference Reinforce Potential Of Accurin Platform To Develop Best-in-Class Therapeutics

BIND Therapeutics' Presentations At Upcoming AACR-NCI-EORTC Conference Reinforce Potential Of Accurin Platform To Develop Best-in-Class Therapeutics

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that four abstracts have been accepted for presentation...

BIND Therapeutics To Report Third Quarter 2015 Financial Results On November 2, 2015

BIND Therapeutics To Report Third Quarter 2015 Financial Results On November 2, 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced it will host a conference call and live audio webcast...

BIND Therapeutics Expands Board Of Directors With Appointment Of Dr. Arthur Tzianabos

BIND Therapeutics Expands Board Of Directors With Appointment Of Dr. Arthur Tzianabos

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced the appointment of Arthur Tzianabos, Ph.

BIND Therapeutics Announces Pfizer Inc. Exercises Option To Advance Nanoparticle-Based Kinase Inhibitor For Treatment Of Solid Tumors

BIND Therapeutics Announces Pfizer Inc. Exercises Option To Advance Nanoparticle-Based Kinase Inhibitor For Treatment Of Solid Tumors

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced that Pfizer Inc.

BIND Therapeutics Initiates Multicenter INSITE 2 Trial With BIND-014 In Four Tumor Histologies

BIND Therapeutics Initiates Multicenter INSITE 2 Trial With BIND-014 In Four Tumor Histologies

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced that patient dosing is underway in the iNSITE 2 trial, a...

BIND Therapeutics To Present At BioCentury's Annual NewsMakers In The Biotech Industry Conference

BIND Therapeutics To Present At BioCentury's Annual NewsMakers In The Biotech Industry Conference

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced that Andrew Hirsch, BIND's president and chief executive...

BIND Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics Reports Second Quarter 2015 Financial Results And Provides Corporate Update

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today reported financial results and business highlights for the second...

BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015

BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins TM, today announced it will host a conference call and live audio webcast on...